ReviewiScience2026
SnoRNAs and SNHGs in bone development, homeostasis, and disease.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small nucleolar RNAs (snoRNAs) guide ribosomal RNA modification and regulate broader RNA-based programs, whereas snoRNA host gene-derived long non-coding RNAs, including SNHG-family transcripts, participate in post-transcriptional and epigenetic regulation. This review synthesizes evidence from skeletal stem/progenitor cells, osteoblast- and osteoclast-lineage models, chondrocytes, bone tumor systems, patient samples, and extracellular vesicle or circulating RNA studies to define how snoRNAs and SNHGs shape bone development, remodeling, and disease. Across osteoporosis, osteoarthritis, bone tumors, and fracture healing, these RNAs influence osteogenic differentiation, osteoclastogenesis, cartilage homeostasis, tumor progression, repair responses, and intercellular communication through ribosome-associated control, ceRNA networks, transcript stability, and chromatin- or protein-associated mechanisms. We also discuss their potential as biomarkers and RNA-targeted therapeutic candidates, together with challenges in annotation, functional validation, delivery, and clinical translation. This framework highlights snoRNAs and SNHGs as regulatory components of skeletal biology and disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.